Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of UGN-102 (TC-3 Gel + MMC) in NMIBC
NCT02307487Phase 2Completed
- Sponsor
- UroGen Pharma
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- DNA Intercalators/Alkylators, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 2 trial of zusduri in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Started Dec 2014; status: completed.
02
Drugs
zusduri
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02307487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307487.